ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow ANIP
ANI Pharmaceuticals, Inc. (ANIP) EV/Sales
As of 16 October 2026, ANI Pharmaceuticals, Inc. (ANIP) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 1.8× (October 2026) to 12.7× (March 2015); the current reading is higher than 0% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.2× | (14.00%) |
| FY2024 | 2.5× | 11.60% |
| FY2023 | 2.2× | (19.60%) |
| FY2022 | 2.8× | (21.29%) |
| FY2021 | 3.6× | 40.94% |
| FY2020 | 2.5× | (39.04%) |
| FY2019 | 4.1× | 50.59% |
| FY2018 | 2.7× | (49.65%) |
| FY2017 | 5.5× | (11.75%) |
| FY2016 | 6.2× | (0.09%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | (1.10%) |
| Mar 2026 | 2.1× | (4.84%) |
| Dec 2025 | 2.2× | (18.48%) |
| Sep 2025 | 2.6× | 16.85% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PRGO Perrigo Company plc compare | 1.3× |
| PAHC Phibro Animal Health Corporation compare | 1.5× |
| ANIP ANI Pharmaceuticals, Inc. | 1.8× |
| PCRX Pacira BioSciences, Inc. compare | 2.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| ALVO Alvotech compare | 9.0× |
| ETON Eton Pharmaceuticals, Inc. compare | 13.2× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)